Hadacol Hangover

As an old horse trader, Louisiana's Dudley J. LeBlanc likes to say that the man who buys a horse has only himself to blame if the horse keels over and dies. Only six weeks ago, a group of Manhattan traders bought the odd-looking business animal that LeBlanc had raised on Hadacol, a patent medicine comparable to a vitamin-enriched Manhattan cocktail (TIME, Sept. 10). This week it looked as if the horse they bought was about dead.

In Manhattan's federal court, Hadacol's purchasers filed a voluntary petition for financial reorganization. After paying LeBlanc $250,000 down (previously announced as $1,100,000) for the company, they made some shocking discoveries. Hadacol's $3,600,000, 15-month profit had somehow mysteriously turned into a $1.8 million second-quarter loss. Worse, they charged that LeBlanc had 1) concealed $2,000,000 of unpaid bills and a tax debt of $656,151 to the Government, 2) falsified Hadacol's records to show $2,272,000 of "accounts receivable" which, in large part, did not exist.

As the court named a trustee to try to get the prostrate horse to its feet again, a new whiplash struck it. The Federal Trade Commission complained that Hadacol's leeringly prurient ballyhoo ("The Hadacol boogie makes you boogie-woogie all the time") is "false, misleading and deceptive" in representing the nostrum as "an effective treatment and cure for scores of ailments and diseases."

This file is automatically generated by a robot program, so reader's discretion is required.